In this study, based on the ICI-treated bladder cancer cohort with mutation and immunotherapy prognosis data (reporter by Samstein et al.), we analyzed the efficacy of ICIs based on NCOR1 alteration status. This evidence concerns the gene NCOR1 and urinary bladder cancer.